TY - JOUR
KW - Adult
KW - Humans
KW - Female
KW - Male
KW - *COVID-19/epidemiology
KW - Retrospective Studies
KW - COVID-19 Testing
KW - Pandemics
KW - SARS-CoV-2
KW - *Lupus Erythematosus, Systemic/complications/epidemiology
KW - vaccination
KW - Covid-19
KW - GENERAL MEDICINE (see Internal Medicine)
KW - health economics
KW - infectious diseases
KW - public health
KW - Rheumatology
AU - A. Rabe
AU - W. Loke
AU - R. Kalyani
AU - R. Tummala
AU - H. Stirnadel-Farrant
AU - J. Were
AU - K. Winthrop
AD - BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK a.rabe@imperial.ac.uk.
Primary Care and Public Health, Imperial College London, London, UK.
East and North Hertfordshire NHS Trust, Lister Hospital, Stevenage, Hertfordshire, UK.
BioPharmaceuticals R&D, AstraZeneca US, Gaithersburg, Maryland, USA.
Oncology Business Unit, Global Medical Affairs, AstraZeneca, Cambridge, UK.
Research Department, Health iQ Limited, London, UK.
Department of Infectious Diseases, Oregon Health & Science University, Portland, Oregon, USA.
AN - 37993165
BT - BMJ Open
C2 - PMC10668278
DO - 10.1136/bmjopen-2022-071072
DP - NLM
ET - 2023/11/23
LA - eng
M1 - 11
N1 - 2044-6055
Rabe, Adrian Paul J
Loke, Wei Jie
Orcid: 0000-0003-2266-5938
Kalyani, Rubana N
Tummala, Raj
Stirnadel-Farrant, Heide A
Were, John
Winthrop, Kevin L
Journal Article
Observational Study
England
BMJ Open. 2023 Nov 22;13(11):e071072. doi: 10.1136/bmjopen-2022-071072.
PY - 2023
SN - 2044-6055
EP - e071072
T2 - BMJ Open
TI - Impact of SARS-CoV-2 infection on patients with systemic lupus erythematosus in England prior to vaccination: a retrospective observational cohort study
VL - 13
ER -